![](https://bloximages.newyork1.vip.townnews.com/wfmz.com/content/tncms/custom/image/b9818ac0-ee9a-11e9-8e9f-a3b831b71481.jpg?resize=600%2C338)
U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics' Proprietary Radiopharmaceutical Cancer Therapy
225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows outstanding preclinical data and FDA IND clearance Phase I…